Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY discusses the details of a current Phase I study (NCT04603001) of LY3410738 in advanced myeloid malignancies. LY3410738 is a first-in-class potent, covalent inhibitor of IDH1-R132. Its unique binding site enables continued potency following common second site IDH mutations, a common cause of relapse for patients on currently approved reversible IDH1 and IDH2 inhibitors. The study, enrolling patients with relapsed or refractory mIDH myeloid malignancies, aims to determine the recommended Phase II dose of LY3410738 and assess the treatment’s anti-tumour activity. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Dr Eytan Stein, MD, has done consultancy for Amgen, Agios Pharmaceuticals, Celgene Pharmaceuticals, Abbvie, Seattle Genetics, Syndax, Genentech, Biotheryx, Novartis, Astellas Pharmaceuticals and Daiichi-Sankyo; has participated in a board of directors or advisory committee with Agios Pharmaceuticals, Celgene Pharmaceuticals, Genentech, Syros, PTC Therapeutics, Novartis, Astellas Pharmaceuticals and Daiichi-Sankyo; and has received research funding from Celgene Pharmaceuticals, Syndax, Bayer, Novartis and Daiichi-Sankyo.